Elevated Substance P Is a Risk Factor for Postoperative Delirium in Patients with Hip Fracture

Wenzheng Zhang,¹ Naixia Hu,² Ya Zhang,³ and Anying Wang⁴

¹Department of Joint Sports Medicine, The Affiliated Taian City Central Hospital of Qingdao University, 271000 Taian, China
²Neurointensive Care Unit, The Second Affiliated Hospital of Shandong First Medical University, 271000 Taian, China
³Department of Pathology, The Second Affiliated Hospital of Shandong First Medical University, 271000 Taian, China
⁴Department of Orthopedics, The Second Affiliated Hospital of Shandong First Medical University, 271000 Taian, China

Correspondence should be addressed to Anying Wang; wanganying008@163.com

Received 25 February 2022; Revised 10 March 2022; Accepted 15 March 2022; Published 31 March 2022

Academic Editor: Min Tang

Copyright © 2022 Wenzheng Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Hip fractures are quite common worldwide, especially among the elderly, and are associated with a high incidence of postoperative delirium, which worsens functional results and increases death. The causes of postoperative delirium in patients with hip fractures are unknown, and a separate pathobiology has been hypothesized. Substance P is a neuropeptide that has been linked to a number of immune-inflammatory and neurological conditions. The purpose of this study was to see if serum substance P levels could predict postoperative delirium in a group of hip fracture patients.

Methods. A total of 148 hip fracture patients were enrolled in the study, all of whom had no substantial pre-existing medical or cognitive issues. Demographic and regular laboratory data were gathered as a starting point. ELISA was used to examine substance P levels before and after surgery (after 1 day). Patients were then divided into two groups: "postoperative delirium" and "no postoperative delirium." Intergroup comparisons, study of delirium prevalence rates in postoperative serum substance P quartile categories, and binary logistic regression for postoperative delirium category as outcome were all done. Results. Except for serum low-density lipoprotein (LDL) levels, there were no statistically significant variations in preoperative substance P levels or other baseline characteristics between the two groups. The "postoperative delirium" group had significantly higher postoperative substance P levels than the "no postoperative delirium" group (46.36 vs. 31.94 pg/ml). There was a significant difference in postoperative delirium rates between the quartile categories of postoperative substance P, with the fourth quartile having the highest rate. Regression analysis revealed that postoperative substance P levels were related with a significantly increased OR (1.265, CI: 1.172-1.283) of postoperative delirium.

Conclusion. In the current sample of hip fracture patients, a higher postoperative serum substance P level was linked to a higher risk of postoperative delirium. Further research into the utility of early postoperative serum substance P as a delirium indicator in hip fracture patients is needed.

1. Introduction

Hip fracture is highly prevalent globally [1–3], particularly among elderly populations, with older females bearing the highest risk [4, 5]. Although declining rates of hip fracture have been reported in several high-income countries [6, 7], it is estimated that global demographic shifts will lead to further increase in hip fracture cases, especially among Asian populations [8]. The projected global burden of hip fracture ranges between approximately 7-21 million by 2050, largely owing to increased life expectancy [9]. Specific risk factors of hip fracture include older age, female gender, low bone mineral density due to osteoporosis or osteopenia, physical inactivity, smoking, high or low BMI, drug, and dietary variables, among others [10, 11]. Delirium is an acute state of confusion and impaired consciousness frequently occurring in hospitalized or severely ill patients [12]. The reported prevalence of delirium in hip fracture patients is high, ranging as high as 20-50% in certain cohorts [13, 14]. Increasing age, institutionalization, pre-existing dementia, and severe...
illness are among significant risk factors for delirium after hip fracture [14, 15]. Patients who experience delirium after hip fracture at increased risk of short- and long-term adverse outcomes including prolonged hospital stay, ICU admission, medical complications, functional impairment, higher mortality, and incident dementia [14, 16] impose tremendous health-care burden and distress. These findings highlight the potential value of preventive strategies to prevent delirium in this group of patients. At the same time, the present understanding of delirium pathobiology remains inadequate [17], and it has been purported that the pathogenesis and clinical course of delirium after hip fracture may differ from that in medically ill patients [18].

Recent evidence indicates that immune-inflammatory and oxidative stress deregulation arising from an aseptic inflammatory cascade may underlie postoperative delirium after hip fracture [19]. The identification of high-value predictive biomarkers of delirium after hip fracture could enable early identification of high-risk patients for tailored approaches for its prevention. The neuropeptide substance P is widely distributed in the central nervous system and is linked to neural inflammatory processes via increased microvascular permeability in several neurological disorders including traumatic brain injury, schizophrenia, stroke, and dementias [20–23]. Thus, the current clinical study was aimed at examining substance P as a predictive biomarker of postoperative delirium after hip fracture.

2. Materials and Methods

2.1. Ethical Approval. The study protocol was preapproved by the Ethical committee of the hospital, and all study procedures were in accordance with the declaration of Helsinki. All subjects or their legal guardians provided signed written informed consent prior to participation.

2.2. Study Population. The present study was designed as an observational study. A total of 261 patients with hip fracture patients among patients were registered, among which 148 patients were recruited for participation in the present study. The inclusion criteria were as follows: (1) definitely diagnosed as hip fracture, (2) meeting standard surgical indications and the patient or family members consenting for surgical treatment, and (3) absence of tumors, autoimmune diseases, or other serious organic diseases. The exclusion criteria were as follows: (1) refusal to participate in the present study, (2) refusal of surgery or no indication for surgery, (3) transfer to another hospital for continuation of treatment, (4) patients with pre-existing delirium before surgery, and (5) pre-existing dementia, tumor, or serious medical illness including heart, liver, lung, or kidney disease. The flow diagram of the study is shown in Figure 1.

2.3. Baseline Clinical and Laboratory Data. Once enrolled, participants were assessed for delirium daily before surgery until they were discharged using the Confusion Assessment Method (CAM). The examining doctors or nurses conducted approximately 20-minute interviews with the participants, combined with information from relatives, and scored the CAM. Based on the presence or absence of postoperative delirium, patients with hip fracture were divided into a delirium group and a delirium-free group. After enrollment, the patient’s clinical baseline characteristics were collected, including age, gender, and low-density lipoprotein (LDL); high-density lipoprotein (HDL); fasting blood glucose (FBG); glycosylated hemoglobin type Alc (HbA1c); and white blood cells (WBC), neutrophil, and lymphocyte counts.

2.4. Sampling and Biochemical Analysis of Serum Substance P Levels. Fasting venous blood was collected early in the morning from the two groups of patients one day before (preoperative) and one day after (postoperative) surgery. The samples were sent directly to the central laboratory on dry ice for analysis or stored at -80°C. The level of serum substance P was analyzed using enzyme-linked immunosorbent assay (ELISA), where the substance P reagent was purchased from a commercial company (Abcam, Cambridge, MA, USA).

2.5. Statistical Analysis. Descriptive data with normal distribution was summarized as the mean ± standard deviation, and the categorical data was expressed as the frequency. The t test was used for comparison between the two groups, and the nonparametric test was used for analysis of categorical data. Postoperative serum substance P was categorized into quartiles, the subjects were divided into 4 groups in accordance, and the prevalence of delirium in each category was analyzed. Binary logistic regression analysis was used to explore the independent predictors of delirium. In the model, age, gender, and baseline laboratory parameters including LDL, HDL, FBG, HbA1c, WBC, neutrophil, lymphocyte counts, and preoperative substance P were entered as independent variables in the regression model. A p value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS 22.0 (SPSS, Chicago, IL, USA).

3. Results

3.1. Baseline Characteristics and Serum Substance P Levels. A total of 148 patients with hip fractures provided complete data, and based on the presence or absence of delirium, 91 patients were grouped into the “no postoperative delirium group,” whereas 57 patients were grouped into the “postoperative delirium group.” The clinical and laboratory characteristics of these patients (age, gender, LDL, HDL, FBG, HbA1c, WBC, neutrophil, lymphocyte) were not statistically significant between the two groups (p > 0.05), while ELISA assays showed that there was no statistically significant difference in the preoperative substance P between the two groups (p > 0.05) (Table 1). The baseline LDL levels of the “no postoperative delirium group” (2.4 ± 0.3 mmol/L) and the “postoperative delirium group” (2.5 ± 0.2 mmol/L) were significantly statistically different (p = 0.028), while after surgery, the postoperative substance P levels of the “no postoperative delirium group” (31.9 ± 4.7 mmol/L) was found to be significantly lower

After enrollment, the patient’s clinical baseline characteristics were collected, including age, gender, and low-density lipoprotein (LDL); high-density lipoprotein (HDL); fasting blood glucose (FBG); glycosylated hemoglobin type Alc (HbA1c); and white blood cells (WBC), neutrophil, and lymphocyte counts.

2.5. Statistical Analysis. Descriptive data with normal distribution was summarized as the mean ± standard deviation, and the categorical data was expressed as the frequency. The t test was used for comparison between the two groups, and the nonparametric test was used for analysis of categorical data. Postoperative serum substance P was analyzed using enzyme-linked immunosorbent assay (ELISA), where the substance P reagent was purchased from a commercial company (Abcam, Cambridge, MA, USA).

3. Results

3.1. Baseline Characteristics and Serum Substance P Levels. A total of 148 patients with hip fractures provided complete data, and based on the presence or absence of delirium, 91 patients were grouped into the “no postoperative delirium group,” whereas 57 patients were grouped into the “postoperative delirium group.” The clinical and laboratory characteristics of these patients (age, gender, LDL, HDL, FBG, HbA1c, WBC, neutrophil, lymphocyte) were not statistically significant between the two groups (p > 0.05), while ELISA assays showed that there was no statistically significant difference in the preoperative substance P between the two groups (p > 0.05) (Table 1). The baseline LDL levels of the “no postoperative delirium group” (2.4 ± 0.3 mmol/L) and the “postoperative delirium group” (2.5 ± 0.2 mmol/L) were significantly statistically different (p = 0.028), while after surgery, the postoperative substance P levels of the “no postoperative delirium group” (31.9 ± 4.7 mmol/L) was found to be significantly lower
3.2. Association of Postoperative Serum Substance P and Risk for Delirium. The prevalence rates of delirium in quartile categories of postoperative serum substance P is shown in Table 2. The prevalence of postoperative delirium showed highly significant variations ($p < 0.001$), with increasing rates of prevalence in sequentially higher quartiles of serum substance P.

3.3. Logistic Regression Analysis of Independent Risk Factors for Postoperative Delirium. Binary logistic regression analysis showed that postoperative serum substance P was an independent predictor of postoperative delirium ($\beta = 0.175$, $p = 0.033$). No significant causal relationship between postoperative delirium and other baseline characteristics was noted ($p > 0.05$) (Table 3).

4. Discussion

The present observational study assessed the predictive value of serum substance P as a biomarker of postoperative delirium among 148 patients operated for hip fracture. The key finding of the study was that postoperative substance P levels at one day after surgery were an independent predictor of delirium occurring during the hospitalization period. As compared to those in the first quartile of postoperative substance P, those in the fourth quartile showed twice the rate of delirium during hospitalization (10% versus 20%). Significantly higher odds of delirium (1.265, CI: 1.172-1.283) were noted for each unit increase in postoperative substance P.
levels, while notably, no relationship was evident between the occurrence of delirium and preoperative substance P levels. Substance P is a neuroregulator from the tachykinin family that is primarily secreted by neural cells along with some immune cells and serves as a key mediator between the neural and immunological systems [24]. High postoperative serum substance P has independently associated with high postoperative pain scores after total knee replacement [25] and rotator cuff repair surgery [26]. Raised serum substance P levels after traumatic brain injury and cerebral hemorrhage are also associated with worse functional outcomes and higher mortality [20, 26–28]. While substance P is primarily secreted by sensory neurons, its biological activities are mediated via its interaction with neurokinin receptors (NKRs), primarily NKR1 [29], which leads to a proinflammatory mediator cascade [24]. Genetic polymorphisms leading to differences in the expression of NKR1 have been documented [30] which may explain the well-recognized variation in circulating substance P levels of both health and diseased states [31].

In the current cohort, the patients presenting with higher levels of postoperative serum substance P plausibly represent a subset of individuals at increased risk of worse inflammatory sequelae in postoperative phase after hip fracture. In an observational study of delirium after hip fracture, a specific cause was identifiable only in 3% of the patients [18], and authors suggested that additional factors such as pain levels or type of anesthesia should be investigated as susceptibility factors. Notably, higher substance P levels are implicated in mediating postoperative pain [25]. In a similar phenomenon, postoperative subjects who manifested increase in substance P levels were found at higher risk for nausea and vomiting as opposed to those whose substance P levels remained unchanged or decreased postoperatively [32]. Although the present study design excluded patients with obvious precipitating factors for postoperative

| Variable                  | Q1       | Q2       | Q3       | Q4       | p values |
|---------------------------|----------|----------|----------|----------|----------|
| Delirium, n (%)           | 10 (27.03) | 12 (32.43) | 15 (40.54) | 20 (54.05) | <0.001   |

**Table 3: Binary logistic regression of risk for postoperative delirium.**

| Variable                  | Regression coefficient | p values | OR        | 95% CI    |
|---------------------------|------------------------|----------|-----------|-----------|
| Age                       | 0.109                  | 0.215    | 1.062     | 0.941-1.093 |
| Gender                    | 0.076                  | 0.380    | 1.051     | 0.926-1.079 |
| LDL                       | 0.142                  | 0.097    | 1.083     | 0.964-1.192 |
| HDL                       | -0.153                 | 0.136    | 0.745     | 0.427-1.081 |
| FBG                       | 0.210                  | 0.233    | 1.078     | 0.943-1.190 |
| HbA1c                     | 0.231                  | 0.372    | 1.064     | 0.929-1.177 |
| WBC                       | 0.137                  | 0.128    | 1.146     | 0.995-1.264 |
| Neutrophil                | 0.158                  | 0.089    | 1.067     | 0.942-1.185 |
| Lymphocyte                | 0.104                  | 0.241    | 1.099     | 0.978-1.136 |
| Preoperative substance P  | 0.136                  | 0.324    | 1.050     | 0.927-1.071 |
| Postoperative substance P | 0.175                  | 0.033*   | 1.265     | 1.172-1.283 |

LDL: low-density lipoprotein; HDL: high-density lipoprotein; FBG: fasting blood glucose; HbA1c: glycosylated hemoglobin type A1c; WBC: white blood cells.

*p < 0.05, **p < 0.001.
delirium including serious medical illness and pre-existing dementia, incident delirium was noted in 38.5% (57/148 subjects), and only LDL levels were found to be significantly different between the groups, pointing to the role of other unidentified and genetic predisposing factors. While specific molecular mechanisms that may underlie the inter-subject variability in the postoperative Substance P level responses warrant further investigation, the present data strongly suggest that high early postoperative substance P level is a valuable biomarker to identify hip fracture patients at higher risk of delirium. Large-scale studies are essential to identify the optimal cut-off values, specificity, and sensitivity of substance P levels that are clinical relevant, in order to facilitate its clinical translation as biomarker of delirium in hip fracture.

The present findings also suggest to a potential role of NK1 receptor antagonists in the preventive management of delirium in postoperative hip fracture patients. The role of NK1 receptor antagonists has been documented in the prevention of postoperative nausea, emesis, and postoperative pain [33, 34]. NK1 and substance P antagonist agents have also been utilized to improve outcomes after traumatic brain injury, particularly when administered in the early postoperative phase [35–37] and found to decrease post-injury cerebral edema by increasing the blood-brain barrier [38]. It may be hypothesized on the basis of the current findings that similar neuroprotection against postoperative delirium in hip fracture could possibly be achieved by the use of NK1 receptor/substance P antagonist agents in the early postoperative phase.

However, the present findings must be viewed considering the limitations of the current study, which include a modest sample size, no dynamic detection of changes in substance P, restricted inclusion criteria, lack of information about additional potential risk factors for postoperative dementia such as method of anesthesia, and laboratory variables like thyroid or albumin levels [39]. In addition, the regression model did not analyze potential interaction effects between the predictive variables, and clinically significant cut-off values for substance P levels were not ascertained. Considering these facts, the present findings must be considered as preliminary data that highlight the potential of substance P as a biomarker of delirium in postoperative hip fracture patients and also suggest the potential role of its blockade in prevention of this devastating complication.

5. Conclusion

In sum, the present observational study demonstrated that higher postoperative serum substance P levels one day after surgery in hip fracture patients significantly increased the odds of delirium during the hospitalization period. These data suggest that substance P and its antagonists may represent clinically valuable entities for translation towards risk stratification, early diagnosis, prevention, and treatment of postoperative dementia in hip fracture patients and therefore merit further investigation.

Data Availability

The data utilized which corroborated this study’s conclusions are accessible once requested from the corresponding author.

Conflicts of Interest

The authors report no conflict of interest.

References

[1] C. A. Brauer, M. Coca-Perraillon, D. M. Cutler, and A. B. Rosen, “Incidence and mortality of hip fractures in the United States,” Journal of the American Medical Association, vol. 302, no. 14, pp. 1573–1579, 2009.
[2] B. Gullberg, O. Johnell, and J. A. Kanis, “World-wide projections for hip fracture,” Osteoporosis International, vol. 7, no. 5, pp. 407–413, 1997.
[3] D. K. Dhanwal, E. M. Dennison, N. C. Harvey, and C. Cooper, “Epidemiology of hip fracture: worldwide geographic variation,” Indian journal of orthopaedics vol., vol. 45, no. 1, pp. 15–22, 2011.
[4] M. E. Farmer, L. R. White, J. A. Brody, and K. R. Bailey, “Race and sex differences in hip fracture incidence,” American Journal of Public Health, vol. 74, no. 12, pp. 1374–1380, 1984.
[5] A. Adeyemi and G. Delhougne, “Incidence and economic burden of intertrochanteric fracture: a Medicare claims database analysis,” IBJS Open Access, vol. 4, no. 1, p. e0045, 2019.
[6] J. A. Stevens and R. A. Rudd, “The impact of decreasing U.S. hip fracture rates on future hip fracture estimates,” Osteoporosis International, vol. 24, no. 10, pp. 2725–2728, 2013.
[7] E. Cassell and A. Clapperton, “A decreasing trend in fall-related hip fracture incidence in Victoria, Australia,” Osteoporosis International, vol. 24, no. 1, pp. 99–109, 2013.
[8] C.-L. Cheung, S. B. Ang, M. Chadha et al., “An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study,” Osteoporosis and Sarcopenia, vol. 4, no. 1, pp. 16–21, 2018.
[9] N. Veronese and S. Maggi, “Epidemiology and social costs of hip fracture,” Injury, vol. 49, no. 8, pp. 1458–1460, 2018.
[10] J. B. Lauritzen, P. A. McNair, and B. Lund, “Risk factors for hip fractures. A review,” Danish Medical Bulletin, vol. 40, 1993.
[11] R. G. Cumming and R. J. Klineberg, “Case-control study of risk factors for hip fractures in the elderly,” American Journal of Epidemiology, vol. 139, no. 5, pp. 493–503, 1994.
[12] O. C. Gleason, “Delirium,” American Family Physician, vol. 67, 2003.
[13] J. Francis, “Delirium in older patients,” Journal of the American Geriatrics Society, vol. 40, no. 8, pp. 829–838, 1992.
[14] C. A. Mosk, M. Mus, J. Vroemen et al., “Dementia and delirium, the outcomes in elderly hip fracture patients,” Clinical Interventions in Aging, vol. 12, pp. 421–430, 2017.
[15] T. O. Smith, A. Cooper, G. Peryer, R. Griffiths, C. Fox, and J. Cross, “Factors predicting incidence of post-operative delirium in older people following hip fracture surgery: a systematic review and meta-analysis,” International Journal of Geriatric Psychiatry, vol. 32, no. 4, pp. 386–396, 2017.
[16] S. J. Lee, S. H. Jung, S.-U. Lee, J.-Y. Lim, K.-S. Yoon, and S. Y. Lee, “Postoperative delirium after hip surgery is a potential risk factor for incident dementia: a systematic review and meta-
analysis of prospective studies,” *Archives of Gerontology and Geriatrics*, vol. 87, article 103977, 2020.

[17] J. R. Maldonado, “Pathoetiologial model of delirium: a comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment,” *Critical Care Clinics*, vol. 24, no. 4, pp. 789–856, 2008.

[18] C. Brauer, R. S. Morrison, S. B. Silberzweig, and A. L. Siu, “The cause of delirium in patients with hip fracture,” *Archives of Internal Medicine*, vol. 160, no. 12, pp. 1856–1860, 2000.

[19] P. Thisayakorn, S. Tangwongchai, S. Tantavisit et al., “Immune, blood cell, and blood gas biomarkers of delirium in elderly individuals with hip fracture surgery,” *Dementia and Geriatric Cognitive Disorders*, vol. 50, no. 2, pp. 161–169, 2021.

[20] L. Lorente, M. M. Martin, T. Almeida et al., “Serum substance P levels are associated with severity and mortality in patients with severe traumatic brain injury,” *Critical Care*, vol. 19, no. 1, pp. 1–8, 2015.

[21] T. Nagamine, “Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics,” *Neuropsychiatric Disease and Treatment*, vol. 4, no. 1, pp. 289–294, 2008.

[22] L. Lorente, M. M. Martin, T. Almeida et al., “Serum levels of substance P and mortality in patients with a severe acute ischemic stroke,” *International Journal of Molecular Sciences*, vol. 17, no. 6, p. 991, 2016.

[23] P. Johansson, E. G. Almqvist, A. Wallin et al., “Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer’s disease,” *Neuroscience Letters*, vol. 609, pp. 58–62, 2015.

[24] A. Mashaghi, A. Marmalidou, M. Tehrani, P. M. Grace, C. Pothoulakis, and R. Dana, “Neuropeptide substance P and the immune response,” *Cellular and Molecular Life Sciences*, vol. 73, no. 22, pp. 4249–4264, 2016.

[25] B. Lisowska, K. Siewruk, and A. Lisowski, “Substance P and acute pain in patients undergoing orthopedic surgery,” *PLOS One*, vol. 11, no. 1, article e0146400, 2016.

[26] F. Franceschi, U. G. Longo, L. Ruzzini et al., “Circulating substance P levels and shoulder joint contracture after arthroscopic repair of the rotator cuff,” *British Journal of Sports Medicine*, vol. 42, no. 9, pp. 742–745, 2008.

[27] L. Lorente, M. M. Martin, A. Pérez-Cejas et al., “Persistently high serum substance P levels and early mortality in patients with severe traumatic brain injury,” *World Neurosurgery*, vol. 132, pp. e613–e617, 2019.

[28] G. Wang, C.-J. He, X.-S. Liang, Y.-F. Zhou, and S.-H. Chen, “Potential role of serum substance P as a favorable biomarker of functional outcome in acute spontaneous intracerebral hemorrhage,” *Clinica Chimica Acta*, vol. 510, pp. 111–116, 2020.

[29] P. W. Mantyh, “Neurobiology of substance P and the NK1 receptor,” *The Journal of Clinical Psychiatry*, vol. 63, 2002.

[30] C. Seneviratne, N. Ait-Daoud, J. Z. Ma, G. Chen, B. A. Johnson, and D. L. Ming, “Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence,” *Neuropsychopharmacology*, vol. 34, no. 11, pp. 2442–2449, 2009.

[31] D. E. Campbell, N. Raftery, R. Tustin III et al., “Measurement of plasma-derived substance P: biological, methodological, and statistical considerations,” *Clinical and Vaccine Immunology*, vol. 13, no. 11, pp. 1197–1203, 2006.

[32] T. Kadota, N. Kakuta, Y. T. Horikawa et al., “Plasma substance P concentrations in patients undergoing general anesthesia: an objective marker associated with postoperative nausea and vomiting,” *JA Clinical Reports*, vol. 2, no. 1, pp. 1–4, 2016.

[33] P. Diemunsch, G. P. Joshi, and J. F. Brichant, “Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting,” *British Journal of Anaesthesia*, vol. 103, no. 1, pp. 7–13, 2009.

[34] R. A. Dionne, M. B. Max, S. M. Gordon et al., “The substance P receptor antagonist CP-99,994 reduces acute postoperative pain,” *Clinical Pharmacology & Therapeutics*, vol. 64, no. 5, pp. 562–568, 1998.

[35] R. Vink and C. Heulev, “Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury,” *Neurotherapeutics*, vol. 7, no. 1, pp. 74–80, 2010.

[36] F. Corrigan, I. Cernak, K. McAteer et al., “NK1 antagonists attenuate tau phosphorylation after blast and repeated concussive injury,” *Scientific Reports*, vol. 11, no. 1, pp. 1–9, 2021.

[37] J. J. Donkin, I. Cernak, P. C. Blumbergs, and R. Vink, “A substance P antagonist reduces axonal injury and improves neurologic outcome when administered up to 12 hours after traumatic brain injury,” *Journal of Neurotrauma*, vol. 28, no. 2, pp. 217–224, 2011.

[38] L. Gabrielian, S. C. Helps, E. Thornton, R. J. Turner, A. V. Leonard, and R. Vink, “Substance P antagonists as a novel intervention for brain edema and raised intracranial pressure,” *Brain Edema XV*, vol. 118, pp. 201–204, 2013.

[39] W. Xu, H. Ma, L. Wang, and C. Zhang, “The risk factors of postoperative delirium in patients with hip fracture: implication for clinical management,” *BMC Musculoskeletal Disorders*, vol. 22, no. 1, pp. 1–7, 2021.